Biomarkers in Amyotrophic Lateral Sclerosis


Naperville, IL -- (SBWIRE) -- 07/21/2014 -- Reportstack, provider of premium market research reports announces the addition of Biomarkers in Amyotrophic Lateral Sclerosis market report to its offering

Biomarkers in Amyotrophic Lateral Sclerosis is focused on the biomarker identification and development in patients with Amyotrophic Lateral Sclerosis (ALS). As a spin-off of Biomarkers: Discovery and Development for a Diagnostic Approach to Neurodegenerative Disorders, this report focuses on the ALS space featured in the parent report, highlighting several biomarker targets under investigation and the progress that has been made in the industry. With regards to employing the use of biomarkers for Parkinson’s Disease, Biomarkers in Amyotrophic Lateral Sclerosis captures market growth of biomarkers, advantages, disadvantages, and validation techniques.

Experts interviewed in this report include:

Dr. Merit Ester Cudkowicz, Chief of Neurology at Massachusetts General Hospital

Dr. Andreas Jeromin, CSO and President of Atlantic Biomarkers

Also available in this report is extensive survey data exclusively conducted for this report. Illustrated by 30 figures captured by an in-depth analysis, this section features insight into targets under investigation, challenges, advantages, and desired features of future diagnostic applications.

To add even more to the robustness of this report, Insight Pharma Reports also garnered a table of clinical trial information and pipeline data related to ALS. This table features companies, targets, clinical phases, and brief target/product descriptions.

To view the table of contents for this market research report please visit

Roger Campbell
United States
Ph: 888-789-6604